Gene · 2621
NIH grants2,018
NIH grants whose papers are about the gene, through NIH's grant-paper links.
441 to 460 of 2,018
Download this page as JSON| Grant | Title | GAS6 papers | Newest fiscal year |
|---|---|---|---|
| R01AR073772 | HIFs in osteocytes | 1 | 2024 |
| R01CA182635 | Targeted therapies in cutaneous melanoma | 1 | 2024 |
| R01CA201402 | The unique roles of the GTP-binding/protein crosslinking enzyme transglutaminase-2 and signaling partners in aggressive cancers | 1 | 2024 |
| R01CA236781 | Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi | 1 | 2024 |
| R01CA238662 | Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662) | 1 | 2024 |
| R01CA239697 | Defining genetic and metabolic requirements of aggressive breast cancer | 1 | 2024 |
| R01CA240952 | Targeting NQO1+ tumor to trigger innate and adaptive immunity | 1 | 2024 |
| R01CA244212 | The role of Nrf2 in mediating resistance to EGFR inhibition in glioblastoma | 1 | 2024 |
| R01CA244780 | Defining the role of type III collagen and the collagen-binding receptor DDR1 in metastatic dormancy | 1 | 2024 |
| R01CA244938 | Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy | 1 | 2024 |
| R01CA245323 | Mechanisms and therapeutic targets of cancer metastasis | 1 | 2024 |
| R01CA247471 | Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer | 1 | 2024 |
| R01CA247550 | Characterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK Cells | 1 | 2024 |
| R01CA247551 | Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC | 1 | 2024 |
| R01CA248158 | Probing the role of epigenomics in Brca1-deficient mammary tumors. | 1 | 2024 |
| R01CA250074 | (PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment | 1 | 2024 |
| R01CA251245 | Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain Inhibition | 1 | 2024 |
| R01CA252874 | Defining and characterizing microenvironmental drivers of disseminated tumor cell dormancy in brain | 1 | 2024 |
| R01DA051889 | Synergistic Mechanisms of chronic Innate Immune Activation in Microglia by Opiates and HIV Infection | 1 | 2024 |
| R01DE030313 | Turning on Persistence: Novel Molecular Determinants that Underpin P. gingivalis Intracellular Survival In Epithelial Cells | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2621/grants?page=23